None listed
Conditions
Sponsors
Korea Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient with osteosarcoma with local recurrence or metastasis - At least one recurrence or metastatic lesion confirmed with 18F-NaF PET/CT - Patients with pulmonary metastases who are unable to treat with surgical resection. - Patients with bone metastasis or local recurrence confirmed progressive disease after radiotherapy or chemotherapy 2. Able to provide informed consent and have signed an approved consent form that conforms to institutional guidelines to ensure compliance 3. Patients from 19 to 80 years of age 4. The Eastern Cooperative Oncology Group (ECOG) _ Performance scale =2 5. Those who satisfy the following conditions in blood test - absolute neutrophil count (ANC)=1,500/µL - Platelet count (PLT)=100,000/µL - hemoglobin=10g/dL (100g/L; 6.2 mmol/L)
Exclusion criteria
Exclusion criteria: 1. A person who is judged to be difficult to perform a clinical trial due to a serious medical condition 2. A person who is determined to have a mental disorder that is difficult to perform PET scan 3. Pre-menopausal women who are pregnant or breastfeeding during screening, or who plan to become pregnant during the test 4. Those participating in other clinical trials at screening and participating in clinical trials should be able to influence the acquisition of 18F-FDG or 18F-NaF PET images (For example, if you are participating in another cohort-based trial that is simply focused on monitoring that you do not receive medicines during screening, you can participate in the current clinical trials.) 5. Those who participated in other clinical trials that may affect the acquisition of 18F-FDG or 18F-NaF PET images from the time of registration until the end of the study, or that may affect the safety assessment following intravenous injection of 223Ra dichloride 6. Those who are likely to influence the acquisition of 18F-FDG PET imaging due to unadjusted diabetes 7. Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation. 8. Vulnerable subjects (researchers or students who participated in research, family members, researchers or students of researchers participating in research)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| standardized uptake value (SUV) of 18F-NaF PET;standardized uptake value (SUV) of 18F-FDG PET | — |
Secondary
| Measure | Time frame |
|---|---|
| ALP (alkaline phosphatase);osteocalcin | — |
Countries
Korea, Republic of
Contacts
Public ContactInki Lee
Korea Cancer Center Hospital
Outcome results
None listed